 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...345678910111213...229230» |
- | bleomycin / Generic mfg.
Preclinical, Journal: Suppression of Ventilation-Induced Diaphragm Fibrosis through the Phosphoinositide 3-Kinase-? in a Murine Bleomycin-Induced Acute Lung Injury Model. (Pubmed Central) - Jun 27, 2024
Therapy targeting PI3K-? may ameliorate MV-associated diaphragm fibrosis.
- || Piqray (alpelisib) / Novartis, Truqap (capivasertib) / Otsuka, AstraZeneca
Review, Journal, Metastases: Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer. (Pubmed Central) - Jun 27, 2024
Herein, we review the common mechanisms of resistance to agents that target the PI3K/AKT/mTOR signalling pathway, elaborate on current management approaches, and discuss ongoing clinical trials attempting to mitigate this significant issue. We highlight the need for additional studies into AKT1 inhibitor resistance in particular.
- || Enjaymo (sutimlimab) / Sanofi, Rituxan (rituximab) / Roche
Review, Journal: The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease. (Pubmed Central) - Jun 26, 2024
Novel drugs include long-acting complement inhibitors, plasma cells, and B-cell targeting agents (proteasome inhibitors, anti-CD38, BTKi, PI3Ki, anti-BAFF). Combination therapy may be the future answer to CAD unmet needs.
- | amphetamine / Generic mfg.
Journal: Cocaine and amphetamine-regulated transcript improves myocardial ischemia-reperfusion injury through PI3K/AKT signalling pathway. (Pubmed Central) - Jun 26, 2024
Further analysis showed that CART upregulated the activation of phospho-AKT, leading to downregulation of lactate dehydrogenase (LDH) release, apoptosis, oxidative stress and excessive autophagy after I/R, which was inhibited by PI3K inhibitor, LY294002. Collectively, CART attenuated MIRI through inhibition of cardiomyocytes apoptosis and excessive autophagy, and the protective effect was dependent on PI3K/AKT signalling pathway.
- | paclitaxel / Generic mfg.
Journal, Combination therapy: Combination therapy using Cel-CSO/Taxol NPs for reversing drug resistance in breast cancer through inhibiting PI3K/AKT/NF-?B/HIF-1? pathway. (Pubmed Central) - Jun 26, 2024
In tumor-bearing mice, NPs exhibited significant curative effects in inducing apoptosis of MCF-7/Taxol tumors which showed a low expression level of P-gp, microtubule-related proteins TUBB3 and Tau. The results indicated that NPs may be a promising strategy to overcome drug resistance caused by P-gp, which improve the antitumor effects in drug-resistant breast cancer.
- | Journal: Avellanin A Has an Antiproliferative Effect on TP-Induced RWPE-1 Cells via the PI3K-Akt Signalling Pathway. (Pubmed Central) - Jun 26, 2024
Furthermore, avellanin A downregulated Cyclin D1 protein expression and upregulated Bax, p21WAF1/Cip1, and p53 proapoptotic protein expression in TP-induced RWPE-1 cells, leading to cell cycle arrest and inhibition of cell proliferation. The results of this study support the use of avellanin A as a potential new drug for the treatment of BPH.
- Enteral Daidzein Attenuates Myocardial Ischemia-reperfusion Injury Via PI3K/Akt Signaling Pathway (Exhibit Hall) - Jun 25, 2024 - Abstract #ASA2024ASA_48;
2B). Conclusion Enteral daidzein showed cardioprotective effects against myocardial IR injury via PI3K/Akt signaling pathway, probably induced by enteral daidzein-induced substances.
- || taselisib (GDC-0032) / Roche
P1 data, Journal, Combination therapy, Metastases: Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. (Pubmed Central) - Jun 24, 2024
Conclusion Enteral daidzein showed cardioprotective effects against myocardial IR injury via PI3K/Akt signaling pathway, probably induced by enteral daidzein-induced substances. PIK3CA targeting with taselisib in combination with HER2-targeted therapies was associated with both promising efficacy and substantial toxicities.
- | Journal: Paeoniflorin protects chicken against APEC-induced acute lung injury by affecting the endocannabinoid system and inhibiting the PI3K/AKT and NF-?B signaling pathways. (Pubmed Central) - Jun 22, 2024
In addition, paeoniflorin significantly reduced the phosphorylation levels of PI3K, AKT, P65, and I?B. In summary, we found that paeoniflorin inhibited APEC-induced ALI, and its mechanism may be through affecting ECs and inhibiting the activation of PI3K/AKT and NF-?B signaling pathways, which provides a new idea for the prevention and treatment of chicken colibacillosis.
- | Journal: Discovery and Optimization of Pyridazinones as PI3K? Selective Inhibitors for Administration by Inhalation. (Pubmed Central) - Jun 22, 2024
selectivity and cellular potency as well as ADME properties in view of administration by inhalation was achieved. Intratracheal administration of lead compound 26 resulted in a promising pharmacokinetic profile, thus demonstrating that the optimization strategy of in vitro profiles successfully translated to an in vivo setting.
- | Journal, Metastases: Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2-?metastatic breast cancer. (Pubmed Central) - Jun 20, 2024
Intratracheal administration of lead compound 26 resulted in a promising pharmacokinetic profile, thus demonstrating that the optimization strategy of in vitro profiles successfully translated to an in vivo setting. Our study provides solid quantitative evidence for the first-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2-?metastatic breast cancer in clinical guidelines.
- | Journal: Thymoquinone affects hypoxia-inducible factor-1? expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways. (Pubmed Central) - Jun 20, 2024
and HSP90; Secondly, TQ reduced the initial expression of HIF-1? protein by inhibiting the PI3K/AKT/mTOR pathway.
- | Journal: Exosomal lncRNA LINC02191 Promotes Laryngeal Squamous cell Carcinoma Progression by Targeting miR-204-5p/RAB22A Axis and Regulating PI3K/Akt/mTOR Pathway. (Pubmed Central) - Jun 19, 2024
Moreover, RAB22A overexpression reversed LINC02191 depletion-triggered suppression of LSCC cell aggressiveness and inactivation of PI3K/Akt/mTOR signaling. In conclusion,
- SHIP1 phosphatase as a Late-Onset Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_1420;
A potential druggable site has been identified between the SHIP1 catalytic and C2 domains that can be targeted allosterically by small molecule compounds. These discoveries will aid in identifying new molecules that can inhibit SHIP1 as a potential therapeutic target for AD.
- Exploring Class-II PI3K Inhibition for the treatment of Alzheimer's Disease: Virtual Screening for PI3KC2A Inhibitors. (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_669;
We've discovered unique molecular structures that inhibit the enzyme. Our findings suggest potential probe molecules for validating the target and developing lead compounds for clinical investigations.
- || Review, Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group. (Pubmed Central) - Jun 19, 2024
Many approaches are still in the early stages of development and further clinical trials will determine their clinical relevance. There is a need to include HR-proficient tumors in ovarian cancer trials and to analyze them in a more targeted manner to provide further evidence for their specific therapy, as this will be crucial in improving the overall prognosis of HGSC and ovarian cancer in general.
- || Review, Journal: Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches. (Pubmed Central) - Jun 19, 2024
Each of the described methods has its advantages and disadvantages and faces problems, such as the inefficient crossing of the blood-brain barrier, various neurological and systemic side effects, and the escape mechanism of the tumor. This work aims to present the current modern treatments of glioblastoma.
- | LY294002 / Eli Lilly
Journal: Butyrate improves recovery from experimental necrotizing enterocolitis by metabolite hesperetin through potential inhibition the PI3K-Akt pathway. (Pubmed Central) - Jun 19, 2024
In summary, the present study demonstrated that butyrate could improve recovery from NEC with a hesperetin metabolite, causing potential inhibition of the phosphorylation of the PI3K-Akt signaling pathway, resulting in the increased expression of TJ proteins. These findings reveal a potential new therapeutic pathway for the treatment of NEC.
- | Journal: The role of autophagy regulated by the PI3K/AKT/mTOR pathway and innate lymphoid cells in eosinophilic chronic sinusitis with nasal polyps. (Pubmed Central) - Jun 18, 2024
The downregulation of autophagy is a pathogenesis of eCRSwNP; therefore, the recovery of normal autophagy levels might be a new target for eCRSwNP therapy. Furthermore, autophagy might inhibit eosinophilic inflammation and tissue remodeling, in part by reducing the number of ILC2s.
- | Piqray (alpelisib) / Novartis
Preclinical, Journal: PI3K inhibitor "alpelisib" alleviates methotrexate induced liver injury in mice and potentiates its cytotoxic effect against MDA-MB-231 triple negative breast cancer cell line. (Pubmed Central) - Jun 16, 2024
RT-PCR revealed the antiproliferative (Bcl-2) and proapoptotic (BAX) potentials of ALP and ALP/MTX combination especially after 24?h. In conclusion, targeting PI3K/AKT pathway is a promising strategy in triple negative breast cancer patients by ameliorating hepatotoxicity and restraining chemoresistance to chemotherapy.
- | LY294002 / Eli Lilly
Biomarker, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker: TFE3/PI3K/Akt/mTOR axis in renal cell carcinoma affects tumor microenvironment. (Pubmed Central) - Jun 16, 2024
When RCC cells were treated with a PI3K inhibitor (LY294002), TFE3 expression increased and phospho-Akt expression decreased. TFE3 is related to the PI3K/Akt pathway in RCC, and our results suggest that PI3K/Akt inhibitors may potentially aid in treatment of patients with RCC by affecting tumor microenvironment.
- | paroxetine / Generic mfg.
Journal, PD(L)-1 Biomarker: Paroxetine alleviates dendritic cell and T lymphocyte activation via GRK2-mediated PI3K-AKT signaling in rheumatoid arthritis. (Pubmed Central) - Jun 16, 2024
TFE3 is related to the PI3K/Akt pathway in RCC, and our results suggest that PI3K/Akt inhibitors may potentially aid in treatment of patients with RCC by affecting tumor microenvironment. Paroxetine exerts an immunosuppressive effect by targeting GRK2, which subsequently inhibits the metabolism-related PI3K-AKT-mTOR pathway of DCs and T cell in RA.
- | Piqray (alpelisib) / Novartis
Journal: Echistatin/BYL-719 impedes epithelial-mesenchymal transition in pulmonary fibrosis induced by silica through modulation of the Integrin ?1/ILK/PI3K signaling pathway. (Pubmed Central) - Jun 16, 2024
These results indicate that Echistatin and BYL 719 can inhibit EMT and pulmonary fibrosis by blocking different stages of Integrin?1 /ILK/PI3K signaling pathway. This indicates that the Integrin ?1/ILK/PI3K signaling pathway is associated with silica-induced EMT and may serve as a potential therapeutic target for silicosis.
- | Mounjaro (tirzepatide) / Eli Lilly
Journal: Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling. (Pubmed Central) - Jun 16, 2024
This indicates that the Integrin ?1/ILK/PI3K signaling pathway is associated with silica-induced EMT and may serve as a potential therapeutic target for silicosis. Collectively, Tirzepatide could alleviate DOX-induced oxidative stress, inflammation and cardiac injury via activating PI3K/Akt signaling pathway and Tirzepatide may be a novel therapeutic target for DOX-induced cardiotoxicity.
- | PI-103 / Roche
Journal: Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer. (Pubmed Central) - Jun 14, 2024
The anti-CD47-PDL1-ADN exhibited greater antitumor efficacy than current treatment options with a PDL1 inhibitor in vivo in an aggressive lung cancer immunocompetent mouse model. Dual antibody-drug-loaded nanotherapeutics can emerge as an attractive platform to improve outcomes with cancer immunotherapy.
- ||| Review, Journal, Adverse events: Endocrine side effects of tumor treatment (Pubmed Central) - Jun 14, 2024
Dual antibody-drug-loaded nanotherapeutics can emerge as an attractive platform to improve outcomes with cancer immunotherapy. A
- | Joenja (leniolisib) / Pharming Group
Journal: Long-Term Treatment With Selective PI3K? Inhibitor Leniolisib in Adults With Activated PI3K? Syndrome. (Pubmed Central) - Jun 14, 2024
P2/3
Collectively, we saw an enhancement in health-related quality of life as well as durable changes in lymphocyte subsets and clinical manifestations, further supporting the use of leniolisib as a long-term therapeutic option for the treatment of APDS. (Funded by Novartis Pharmaceuticals Corporation and Pharming Group NV; ClinicalTrials.gov identifier: NCT02859727.).
- | Journal: PI3 kinase inhibitor PI828 uncouples aminergic GPCRs and Ca2+ mobilization irrespectively of its primary target. (Pubmed Central) - Jun 13, 2024
As demonstrated with these tools, wortmannin could be bound in the extracellular vestibule at the muscarinic M3 receptor but this did not preclude binding of ACh to the M3 receptor followed by its activation. In contrast, PI828 could sterically block the passage of ACh into the allosteric site, preventing activation of the muscarinic M3 receptor.
- || Review, Journal: Targeted Therapies in Low-Grade Serous Ovarian Cancers. (Pubmed Central) - Jun 13, 2024
Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.
- | dexamethasone / Generic mfg.
Journal: Discovery of Novel Azaindoles as Potent and Selective PI3K? Inhibitors for Treatment of Multiple Sclerosis. (Pubmed Central) - Jun 13, 2024
Overall, this work provides a new structural PI3K? inhibitor and a new vision for MS therapy.
- | Journal: Two Undescribed Coumarins from Notopterygium incisum with Anti-inflammatory Activity. (Pubmed Central) - Jun 13, 2024
1-2 exhibits obviously anti-inflammatory activity by inhibiting the expression of inflammatory mediators (COX-2, iNOS), as well as reducing the release of NO and the accumulation of ROS in cells. Western blotting analysis revealed that 2 could inhibit the PI3K/AKT pathway by reducing the expression of p-PI3K and p-AKT.
- | ciprofloxacin oral / Generic mfg., indomethacin / Generic mfg.
Preclinical, Journal: Indomethacin Combined with Ciprofloxacin Improves the Prognosis of Mice under Severe Traumatic Infection via the PI3K/Akt Pathway in Macrophages. (Pubmed Central) - Jun 12, 2024
IND plus CIP can regulate macrophage function through the PI3K/Akt signalling pathway and improve the prognosis of severe traumatic infected mice. This may be a new therapeutic strategy for the prevention and treatment of severe traumatic infection.
- | LY294002 / Eli Lilly
Journal: Keratinocyte differentiation factor 1 enhances cervical cancer cell viability and migration by activating the PI3K/AKT pathway. (Pubmed Central) - Jun 12, 2024
A PI3K inhibitor (LY294002) was used to detect the effect of KDF1 on the phosphoinositide 3-kinase (PI3K)/Protein Kinase B (AKT) pathway...Additionally, the PI3K inhibitor reduced the proliferation, invasion, and migration of HeLa cells overexpressing KDF1 (p?<?0.01). KDF1 enhances cervical cancer viability and migration by activating the PI3K/AKT pathway, and may serve as a therapeutic target for patients with cervical cancer.
- | MK-2206 / Merck (MSD), LY294002 / Eli Lilly
Preclinical, Journal: Wogonin Mitigates Acetaminophen-Induced Liver Injury in Mice through Inhibition of the PI3K/AKT Signaling Pathway. (Pubmed Central) - Jun 11, 2024
KDF1 enhances cervical cancer viability and migration by activating the PI3K/AKT pathway, and may serve as a therapeutic target for patients with cervical cancer. Wogonin alleviated AILI and APAP-induced hepatotoxicity in mice through the PI3K/AKT signaling pathway.
- | Journal: Neurotrophin-3 Rescues Striatal Synaptic Plasticity in Model of Neurodegeneration by PLC Signaling Activation. (Pubmed Central) - Jun 11, 2024
Wogonin alleviated AILI and APAP-induced hepatotoxicity in mice through the PI3K/AKT signaling pathway. Our finding highlights the specific involvement of the PLC pathway in the neuroprotective effects of NT-3 in mitigating synaptic dysfunction under neurodegenerative conditions.
- | Journal: Patients with acquired pure red cell aplasia respond to PI3K? inhibitor rapidly. (Pubmed Central) - Jun 11, 2024
Our finding highlights the specific involvement of the PLC pathway in the neuroprotective effects of NT-3 in mitigating synaptic dysfunction under neurodegenerative conditions. No abstract available
- | Journal: Asiatic acid inhibits osteosarcoma cell migration and invasion via the AKT/Sp1/MMP1 axis. (Pubmed Central) - Jun 11, 2024
AA inhibited AKT phosphorylation, and treatment with a PI3K inhibitor (wortmannin) increased the anti-invasive effect of AA on osteosarcoma cells via the p-AKT/Sp1/MMP1 axis. Thus, AA exhibits the potential for use as an anticancer drug against human osteosarcoma.
- | Zejula (niraparib) / GSK, J&J, Aliqopa (copanlisib) / Bayer
Trial completion date, Trial primary completion date: Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 11, 2024
P1, N=31, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Thus, AA exhibits the potential for use as an anticancer drug against human osteosarcoma. Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- | Journal: Mesenchymal Stem Cell-Derived Exosomes as Drug Carriers for Delivering miRNA-29b to Ameliorate Inflammation in Corneal Injury Via Activating Autophagy. (Pubmed Central) - Jun 10, 2024
In addition, overexpression of miR-29b-3p prevented iHCECs from autophagy impairment and inflammatory injury. Exos from BMSCs carrying miR-29b-3p can significantly improve the therapeutic effect on CI via activating autophagy and further inhibiting corneal inflammation and fibrosis.
- | etoposide IV / Generic mfg.
Journal: Ergothioneine Protects Against UV-Induced Oxidative Stress Through the PI3K/AKT/Nrf2 Signaling Pathway. (Pubmed Central) - Jun 10, 2024
Moreover, a PI3K inhibitor blocked EGT protection against etoposide-induced cell death. The study showed EGT may play an important protective role against cell damage or death through the PI3K/Akt/Nrf2 signaling pathway in skin.
- ||| Piqray (alpelisib) / Novartis
Review, Journal, Adverse events: Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature. (Pubmed Central) - Jun 9, 2024
Addition of a preemptive antihyperglycemic or escalation in those previously on antihyperglycemic medications is beneficial in decreasing the severity of hyperglycemia with alpelisib. Further study investigating risk factors is warranted to better elucidate which patients require preemptive therapy.
- | LY294002 / Eli Lilly
Journal: Anti-tumor effect of dandelion flavone on multiple myeloma cells and its mechanism. (Pubmed Central) - Jun 8, 2024
Further study investigating risk factors is warranted to better elucidate which patients require preemptive therapy. By modulating the PI3K/AKT pathway, DF effectively inhibits MM cell proliferation, migration, and invasion, and induces apoptosis, establishing a novel therapeutic strategy for MM based on traditional Chinese medicine.
- | Journal: Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia. (Pubmed Central) - Jun 8, 2024
CLL remains an incurable disease and effective treatment options after relapse or development of TKI resistance are greatly needed. This review provides an overview of BCR signaling, a summary of the current therapeutic landscape, and a discussion of the ongoing trials targeting BCR-associated kinases.
- || Brukinsa (zanubrutinib) / BeiGene
Review, Journal, IO biomarker: Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. (Pubmed Central) - Jun 7, 2024
Second-generation inhibitors, such as acalabrutinib and zanubrutinib, offer improved selectivity and reduced side effects...Overall, advancements in BTK-targeted therapies provide hope for improved outcomes in patients with B-cell malignancies and a promising avenue to address drug resistance. Further research is needed to optimize combination therapies and identify optimal treatment regimens.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Brukinsa (zanubrutinib) / BeiGene, BGB-10188 / BeiGene
Trial completion date, Combination therapy, Monotherapy: BGB-A317-3111-10188-101: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov) - Jun 7, 2024
P1/2, N=113, Recruiting, Sponsor: BeiGene
Further research is needed to optimize combination therapies and identify optimal treatment regimens. Trial completion date: Feb 2025 --> Dec 2025
- | Journal, IO biomarker: Synthesis of triazole AD-1 derivatives and its mechanism of mediating DNA damage of ROS in lung cancer cells. (Pubmed Central) - Jun 6, 2024
Network pharmacology and molecular docking predicted the potential signaling pathways and ligand-receptor interactions, and the results of western blotting showed that 6a inhibited the PI3K/Akt/Bcl-2 signaling pathway by decreasing PI3K and Bcl-2 and total level of Akt expression, while Bax and Cyt c were increasing in 6a-treated A549 cells. As mentioned above, 6a has a potent inhibitory effect in A549 cells through induction of DNA damage, apoptosis via ROS generation and modulation of PI3K/Akt/Bcl-2 signaling pathway.
- | eganelisib (IPI-549) / Infinity Pharma
Journal: Targetable leukaemia dependency on noncanonical PI3K? signalling. (Pubmed Central) - Jun 6, 2024
In addition, the combination of eganelisib and cytarabine prolongs survival over either agent alone, even in patient-derived leukaemia xenografts with low baseline PIK3R5 expression, as residual leukaemia cells after cytarabine treatment have elevated G protein-coupled purinergic receptor activity and PAK1 phosphorylation. Together, our study reveals a targetable dependency on PI3K?-PAK1 signalling that is amenable to near-term evaluation in patients with acute leukaemia.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Preclinical, Journal, Combination therapy: Evaluation of copanlisib in combination with eribulin in triple negative breast cancer patient-derived xenograft models. (Pubmed Central) - Jun 6, 2024
These data support further clinical development for the combination of copanlisib and eribulin. These data led to a phase I/II trial of copanlisib and eribulin in patients with metastatic TNBC.
- || RLY-2608 / Relay Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: ReDiscover: First-in-Human Study of Mutant-selective PI3K? Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (clinicaltrials.gov) - Jun 6, 2024
P1, N=400, Recruiting, Sponsor: Relay Therapeutics, Inc.
These data led to a phase I/II trial of copanlisib and eribulin in patients with metastatic TNBC. Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Jan 2025 --> Dec 2025
- | Piqray (alpelisib) / Novartis
Journal, Metastases: Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity. (Pubmed Central) - Jun 5, 2024
Alpelisib represents an active treatment option in patients with recurrent gynecological cancers harboring a PIK3CA mutation. These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers.